1
|
Zhan W, Li D, Saha P, Wang R, Zhang H, Ajay AK, Deban C, Sukenick G, Azzi J, Lin G. Discovery of Highly Selective Inhibitors of the Human Constitutive Proteasome β5c Chymotryptic Subunit. J Med Chem 2023; 66:1172-1185. [PMID: 36608337 PMCID: PMC10157300 DOI: 10.1021/acs.jmedchem.2c00733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
We describe our discovery and development of potent and highly selective inhibitors of human constitutive proteasome chymotryptic activity (β5c). Structure-activity relationship studies of the novel class of inhibitors focused on optimization of N-cap, C-cap, and side chain of the chemophore asparagine. Compound 32 is the most potent and selective β5c inhibitor in this study. A docking study provides a structure rationale for potency and selectivity. Kinetic studies show a reversible and noncompetitive inhibition mechanism. It enters the cells to engage the proteasome target, potently and selectively kills multiple myeloma cells, and does so by synergizing with a β5i-selective inhibitor.
Collapse
Affiliation(s)
- Wenhu Zhan
- Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, United States
| | - Daqiang Li
- Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, United States
| | - Priya Saha
- Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, United States
| | - Rong Wang
- NMR Analytical Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
| | - Hao Zhang
- Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, United States
| | - Amrendra K. Ajay
- Renal Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Christa Deban
- Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - George Sukenick
- NMR Analytical Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
| | - Jamil Azzi
- Renal Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
| | - Gang Lin
- Department of Microbiology & Immunology, Weill Cornell Medicine, 1300 York Ave., New York, NY 10065, United States
| |
Collapse
|
2
|
Kisselev AF. Site-Specific Proteasome Inhibitors. Biomolecules 2021; 12:54. [PMID: 35053202 PMCID: PMC8773591 DOI: 10.3390/biom12010054] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 12/22/2021] [Accepted: 12/27/2021] [Indexed: 12/14/2022] Open
Abstract
Proteasome is a multi-subunit protein degradation machine, which plays a key role in the maintenance of protein homeostasis and, through degradation of regulatory proteins, in the regulation of numerous cell functions. Proteasome inhibitors are essential tools for biomedical research. Three proteasome inhibitors, bortezomib, carfilzomib, and ixazomib are approved by the FDA for the treatment of multiple myeloma; another inhibitor, marizomib, is undergoing clinical trials. The proteolytic core of the proteasome has three pairs of active sites, β5, β2, and β1. All clinical inhibitors and inhibitors that are widely used as research tools (e.g., epoxomicin, MG-132) inhibit multiple active sites and have been extensively reviewed in the past. In the past decade, highly specific inhibitors of individual active sites and the distinct active sites of the lymphoid tissue-specific immunoproteasome have been developed. Here, we provide a comprehensive review of these site-specific inhibitors of mammalian proteasomes and describe their utilization in the studies of the biology of the active sites and their roles as drug targets for the treatment of different diseases.
Collapse
Affiliation(s)
- Alexei F Kisselev
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA
| |
Collapse
|
3
|
Reboud-Ravaux M. [The proteasome - structural aspects and inhibitors: a second life for a validated drug target]. Biol Aujourdhui 2021; 215:1-23. [PMID: 34397372 DOI: 10.1051/jbio/2021005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Indexed: 02/06/2023]
Abstract
The proteasome is the central component of the adaptable ubiquitin proteasome system (UPS) discovered in the 1980's. It sustains protein homeostasis (proteostasis) under a large variety of physiological and pathological conditions. Its dysregulation has been often associated to various human diseases. Its potential regulation by modulators has emerged as promising avenue to develop treatments of various pathologies. The FDA approval in 2003 of the proteasome inhibitor bortezomib to treat multiple myeloma, then mantle lymphoma in 2006, has considerably increased the clinical interest of proteasome inhibition. Second-generation proteasome inhibitors (carfilzomib and ixazomib) have been approved to overcome bortezomib resistance and improved toxicity profile and route of administration. Selective inhibition of immunoproteasome is a promising approach towards the development of immunomodulatory drugs. The design of these drugs relies greatly on the elucidation of high-resolution structures of the targeted proteasomes. The ATPase-dependent 26S proteasome (2.4 MDa) consists of a 20S proteolytic core and one or two 19S regulatory particles. The 20S core contains three types of catalytic sites. In recent years, due to technical advances especially in atomic cryo-electron microscopy, significant progress has been made in the understanding of 26S proteasome structure and its dynamics. Stepwise conformational changes of the 19S particle induced by ATP hydrolysis lead to substrate translocation, 20S pore opening and processive protein degradation by the 20S proteolytic subunits (2β1, 2β2 and 2β5). A large variety of structurally different inhibitors, both natural products or synthetic compounds targeting immuno- and constitutive proteasomes, has been discovered. The latest advances in this drug discovery are presented. Knowledge about structures, inhibition mechanism and detailed biological regulations of proteasomes can guide strategies for the development of next-generation inhibitors to treat human diseases, especially cancers, immune disorders and pathogen infections. Proteasome activators are also potentially applicable to the reduction of proteotoxic stresses in neurodegeneration and aging.
Collapse
Affiliation(s)
- Michèle Reboud-Ravaux
- Sorbonne Université, Institut de Biologie Paris Seine (IBPS), CNRS UMR 8256, Inserm ERL U1164, 7 quai Saint Bernard, 75252 Paris Cedex 05, France
| |
Collapse
|
4
|
Uysal S, Soyer Z, Saylam M, Tarikogullari AH, Yilmaz S, Kirmizibayrak PB. Design, synthesis and biological evaluation of novel naphthoquinone-4-aminobenzensulfonamide/carboxamide derivatives as proteasome inhibitors. Eur J Med Chem 2020; 209:112890. [PMID: 33039723 DOI: 10.1016/j.ejmech.2020.112890] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Revised: 09/23/2020] [Accepted: 09/24/2020] [Indexed: 10/23/2022]
Abstract
A series of novel 4-aminobenzensulfonamide/carboxamide derivatives bearing naphthoquinone pharmacophore were designed, sythesized and evaluated for their proteasome inhibitory and antiproliferative activities against human breast cancer cell line (MCF-7). The structures of the synthesized compounds were confirmed by spectral and elemental analyses. The proteasome inhibitory activity studies were carried out using cell-based assay. The antiproteasomal activity results revealed that most of the compounds exhibited inhibitory activity with different percentages against the caspase-like (C-L, β1 subunit), trypsin-like (T-L, β2 subunit) and chymotrypsin-like (ChT-L, β5 subunit) activities of proteasome. Among the tested compounds, compound 14 bearing 5-chloro-2-pyridyl ring on the nitrogen atom of sulfonamide group is the most active compound in the series and displayed higher inhibition with IC50 values of 9.90 ± 0.61, 44.83 ± 4.23 and 22.27 ± 0.15 μM against ChT-L, C-L and T-L activities of proteasome compared to the lead compound PI-083 (IC50 = 12.47 ± 0.21, 53.12 ± 2.56 and 26.37 ± 0.5 μM), respectively. The antiproliferative activity was also determined by MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay in vitro. According to the antiproliferative activity results, all of the compounds exhibited cell growth inhibitory activity in a range of IC50 = 1.72 ± 0.14-20.8 ± 0.5 μM and compounds 13 and 28 were found to be the most active compounds with IC50 values of 1.79 ± 0.21 and 1.72 ± 0.14 μM, respectively. Furthermore, molecular modeling studies were carried out for the compounds 13, 14 and 28 to investigate the ligand-enzyme binding interactions.
Collapse
Affiliation(s)
- Sirin Uysal
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, İzmir, Turkey
| | - Zeynep Soyer
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, İzmir, Turkey.
| | - Merve Saylam
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İzmir Katip Celebi University, İzmir, Turkey
| | - Ayse H Tarikogullari
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, İzmir, Turkey
| | - Sinem Yilmaz
- Department of Biotechnology, Institute of Science, Ege University, İzmir, Turkey; Department of Bioengineering, Faculty of Engineering, University of Alaaddin Keykubat, Antalya, Turkey
| | | |
Collapse
|
5
|
Kiwada T, Katakasu H, Okumura S, Odani A. Characterization of platinum(II) complexes exhibiting inhibitory activity against the 20S proteasome. ROYAL SOCIETY OPEN SCIENCE 2020; 7:200545. [PMID: 32968518 PMCID: PMC7481701 DOI: 10.1098/rsos.200545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Accepted: 07/23/2020] [Indexed: 06/11/2023]
Abstract
Proteasome inhibitors are useful for biochemical research and clinical treatment. In our previous study, we reported that the 4N-coordinated platinum complexes with anthracenyl ring and heterocycle exhibited proteasome-inhibitory activity. In the present study, the structure-activity relationships and characterization of these complexes were determined for the elucidation of the role of aromatic ligands. Lineweaver-Burk analysis revealed that the chemical structure of heterocycles affects the binding mode of platinum complexes. Platinum complexes with anthracenyl ring and pyridine showed competitive inhibition, although platinum complexes with anthracenyl ring and phenanthroline showed non-competitive inhibition. The structure-activity relationships demonstrated that anthracenyl moiety plays a crucial role in proteasome-inhibitory activity. The platinum complexes with naphthyl or phenyl rings exhibited lower inhibitory activities than the platinum complex with anthracenyl ring. The reactivity with N-acetylcysteine varied according to the chemical structure of complexes.
Collapse
Affiliation(s)
- Tatsuto Kiwada
- Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
| | - Hiromu Katakasu
- School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
| | - Serina Okumura
- School of Pharmacy, College of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
| | - Akira Odani
- Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
| |
Collapse
|
6
|
Boualia I, Debache A, Boulcina R, Roisnel T, Berrée F, Vidal J, Carboni B. Synthesis of novel 3-(quinazol-2-yl)-quinolines via SNAr and aluminum chloride-induced (hetero) arylation reactions and biological evaluation as proteasome inhibitors. Tetrahedron Lett 2020. [DOI: 10.1016/j.tetlet.2020.151805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
7
|
Chemical Patterns of Proteasome Inhibitors: Lessons Learned from Two Decades of Drug Design. Int J Mol Sci 2019; 20:ijms20215326. [PMID: 31731563 PMCID: PMC6862029 DOI: 10.3390/ijms20215326] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Revised: 10/17/2019] [Accepted: 10/23/2019] [Indexed: 12/23/2022] Open
Abstract
Drug discovery now faces a new challenge, where the availability of experimental data is no longer the limiting step, and instead, making sense of the data has gained a new level of importance, propelled by the extensive incorporation of cheminformatics and bioinformatics methodologies into the drug discovery and development pipeline. These enable, for example, the inference of structure-activity relationships that can be useful in the discovery of new drug candidates. One of the therapeutic applications that could benefit from this type of data mining is proteasome inhibition, given that multiple compounds have been designed and tested for the last 20 years, and this collection of data is yet to be subjected to such type of assessment. This study presents a retrospective overview of two decades of proteasome inhibitors development (680 compounds), in order to gather what could be learned from them and apply this knowledge to any future drug discovery on this subject. Our analysis focused on how different chemical descriptors coupled with statistical tools can be used to extract interesting patterns of activity. Multiple instances of the structure-activity relationship were observed in this dataset, either for isolated molecular descriptors (e.g., molecular refractivity and topological polar surface area) as well as scaffold similarity or chemical space overlap. Building a decision tree allowed the identification of two meaningful decision rules that describe the chemical parameters associated with high activity. Additionally, a characterization of the prevalence of key functional groups gives insight into global patterns followed in drug discovery projects, and highlights some systematically underexplored parts of the chemical space. The various chemical patterns identified provided useful insight that can be applied in future drug discovery projects, and give an overview of what has been done so far.
Collapse
|
8
|
Amara R, Awad H, Chaker D, Bentabed‐Ababsa G, Lassagne F, Erb W, Chevallier F, Roisnel T, Dorcet V, Fajloun Z, Vidal J, Mongin F. Conversion of Isatins to Tryptanthrins, Heterocycles Endowed with a Myriad of Bioactivities. European J Org Chem 2019. [DOI: 10.1002/ejoc.201900352] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Rim Amara
- Univ Rennes, CNRS ISCR (Institut des Sciences Chimiques de Rennes) ‐ UMR 6226 35000 Rennes France
- Laboratoire de Synthèse Organique Appliquée Faculté des Sciences Exactes et Appliquées Université Oran1 Ahmed Ben Bella BP 1524 El M'Naouer 31000 Oran Algeria
| | - Haçan Awad
- Faculty of Sciences 3 Lebanese University Campus El‐Kobbeh Tripoli Lebanon
| | - Diana Chaker
- Laboratory of Applied Biotechnology Azm Center for Research in Biotechnology and its Applications, EDST Lebanese University 1300 Tripoli Lebanon
| | - Ghenia Bentabed‐Ababsa
- Laboratoire de Synthèse Organique Appliquée Faculté des Sciences Exactes et Appliquées Université Oran1 Ahmed Ben Bella BP 1524 El M'Naouer 31000 Oran Algeria
| | - Frédéric Lassagne
- Univ Rennes, CNRS ISCR (Institut des Sciences Chimiques de Rennes) ‐ UMR 6226 35000 Rennes France
| | - William Erb
- Univ Rennes, CNRS ISCR (Institut des Sciences Chimiques de Rennes) ‐ UMR 6226 35000 Rennes France
| | - Floris Chevallier
- Univ Rennes, CNRS ISCR (Institut des Sciences Chimiques de Rennes) ‐ UMR 6226 35000 Rennes France
| | - Thierry Roisnel
- Univ Rennes, CNRS ISCR (Institut des Sciences Chimiques de Rennes) ‐ UMR 6226 35000 Rennes France
| | - Vincent Dorcet
- Univ Rennes, CNRS ISCR (Institut des Sciences Chimiques de Rennes) ‐ UMR 6226 35000 Rennes France
| | - Ziad Fajloun
- Faculty of Sciences 3 Lebanese University Campus El‐Kobbeh Tripoli Lebanon
- Laboratory of Applied Biotechnology Azm Center for Research in Biotechnology and its Applications, EDST Lebanese University 1300 Tripoli Lebanon
| | - Joëlle Vidal
- Univ Rennes, CNRS ISCR (Institut des Sciences Chimiques de Rennes) ‐ UMR 6226 35000 Rennes France
| | - Florence Mongin
- Univ Rennes, CNRS ISCR (Institut des Sciences Chimiques de Rennes) ‐ UMR 6226 35000 Rennes France
| |
Collapse
|
9
|
Yu J, Xu L, Hong D, Zhang X, Liu J, Li D, Li J, Zhou Y, Liu T. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors. Eur J Med Chem 2018; 161:543-558. [PMID: 30391816 DOI: 10.1016/j.ejmech.2018.10.056] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2018] [Revised: 10/22/2018] [Accepted: 10/23/2018] [Indexed: 12/31/2022]
Abstract
A series of novel phenol ether derivatives were designed, synthesized, and evaluated as non-covalent proteasome inhibitors. Most compounds exhibited moderate to excellent proteasome inhibitory activity. In particular, compound 18x proved to be the most potent compound (chymotrypsin-like: IC50 = 49 nM), exhibiting a 2-fold higher potency compared to the reported PI-1840. Besides, compound 18x exhibited excellent metabolic stability and selective anti-proliferative activity against solid cancer cell lines including HepG2 and HGC27, providing incentive for the further development as a potential anticancer agent against solid cancers.
Collapse
Affiliation(s)
- Jianjun Yu
- ZJU-ENS Joint Laboratory of Medicinal Chemistry, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China
| | - Lei Xu
- School of Life Science and Technology, ShanghaiTech University, Shanghai, 201203, PR China; National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, PR China; University of Chinese Academy of Sciences, Graduate School, No. 19A Yuquan Road, Beijing, 100049, PR China
| | - Duidui Hong
- ZJU-ENS Joint Laboratory of Medicinal Chemistry, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China
| | - Xiaotuan Zhang
- National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, PR China; University of Chinese Academy of Sciences, Graduate School, No. 19A Yuquan Road, Beijing, 100049, PR China
| | - Jieyu Liu
- National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, PR China; University of Chinese Academy of Sciences, Graduate School, No. 19A Yuquan Road, Beijing, 100049, PR China
| | - Daqiang Li
- ZJU-ENS Joint Laboratory of Medicinal Chemistry, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China
| | - Jia Li
- National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, PR China; University of Chinese Academy of Sciences, Graduate School, No. 19A Yuquan Road, Beijing, 100049, PR China
| | - Yubo Zhou
- National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, PR China; University of Chinese Academy of Sciences, Graduate School, No. 19A Yuquan Road, Beijing, 100049, PR China.
| | - Tao Liu
- ZJU-ENS Joint Laboratory of Medicinal Chemistry, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
| |
Collapse
|
10
|
Villoutreix BO, Khatib AM, Cheng Y, Miteva MA, Maréchal X, Vidal J, Reboud-Ravaux M. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes. Oncotarget 2018; 8:10437-10449. [PMID: 28060729 PMCID: PMC5354670 DOI: 10.18632/oncotarget.14428] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Accepted: 12/13/2016] [Indexed: 01/04/2023] Open
Abstract
A structure-based virtual screening of over 400,000 small molecules against the constitutive proteasome activity followed by in vitro assays led to the discovery of a family of proteasome inhibitors with a sulfonyl piperazine scaffold. Some members of this family of small non-peptidic inhibitors were found to act selectively on the β2 trypsin-like catalytic site with a preference for the immunoproteasome β2i over the constitutive proteasome β2c, while some act on the β5 site and post-acid site β1 of both, the immunoproteasome and the constitutive proteasome. Anti-proliferative and anti-invasive effects on tumor cells were investigated and observed for two compounds. We report novel chemical inhibitors able to interfere with the three types of active centers of both, the immuno- and constitutive proteasomes. Identifying and analyzing a novel scaffold with decorations able to shift the binders’ active site selectivity is essential to design a future generation of proteasome inhibitors able to distinguish the immunoproteasome from the constitutive proteasome.
Collapse
Affiliation(s)
| | | | - Yan Cheng
- Sorbonne Universités, UPMC Université Paris 6, UMR 8256, ERL U1164, B2A, IBPS, Paris, France
| | - Maria A Miteva
- INSERM, U 973, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Xavier Maréchal
- Sorbonne Universités, UPMC Université Paris 6, UMR 8256, ERL U1164, B2A, IBPS, Paris, France
| | - Joëlle Vidal
- Institut des Sciences Chimiques de Rennes, Université de Rennes 1, UMR-CNRS 6226, Rennes, France
| | - Michèle Reboud-Ravaux
- Sorbonne Universités, UPMC Université Paris 6, UMR 8256, ERL U1164, B2A, IBPS, Paris, France
| |
Collapse
|
11
|
Bosc E, Nastri J, Lefort V, Valli M, Contiguiba F, Pioli R, Furlan M, Bolzani VDS, El Amri C, Reboud-Ravaux M. Piperlongumine and some of its analogs inhibit selectively the human immunoproteasome over the constitutive proteasome. Biochem Biophys Res Commun 2018; 496:961-966. [PMID: 29355526 DOI: 10.1016/j.bbrc.2018.01.100] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2018] [Accepted: 01/15/2018] [Indexed: 01/09/2023]
Abstract
The natural small molecule piperlongumine A is toxic selectively to cancer cells in vitro and in vivo. This toxicity has been correlated with cancer cell ROS, DNA damage and apoptotic cell death increases. We demonstrate here a new mechanistic property of piperlongumine: it inhibits selectively human immunoproteasome with no noticeable inhibition of human constitutive proteasome. This result suggests that immunoproteasome inhibition, a mechanism independent of ROS elevation, may also partly play a role in the anticancer effects observed with piperlongumine. Structure-activity relationships of piperlongumine analogs suggest that the lactam (piperidonic) ring of piperlongumine A may be replaced by the linear olefin -NHCO-CH2=CH2 to improve both in vitro inhibitory efficiency against immunoproteasome and cellular toxicity.
Collapse
Affiliation(s)
- Elodie Bosc
- Sorbonne Université, UPMC Univ Paris 06-CNRS, IBPS, UMR 8256, Inserm ERL1164, B2A, 7 Quai Saint Bernard, F75005 Paris, France
| | - Jhennifer Nastri
- Nuclei of Bioassays, Biosynthesis and Ecophysiology of Natural Products (NuBBE), Department of Organic Chemistry, Institute of Chemistry, Sao Paulo State University - UNESP, 14800-060, Araraquara, SP, Brazil
| | - Valérie Lefort
- Sorbonne Université, UPMC Univ Paris 06-CNRS, IBPS, UMR 8256, Inserm ERL1164, B2A, 7 Quai Saint Bernard, F75005 Paris, France
| | - Marilia Valli
- Nuclei of Bioassays, Biosynthesis and Ecophysiology of Natural Products (NuBBE), Department of Organic Chemistry, Institute of Chemistry, Sao Paulo State University - UNESP, 14800-060, Araraquara, SP, Brazil
| | - Fernando Contiguiba
- Institute for Natural Products Research Walter Mors, Health Sciences Center - HSC, Federal University of Rio de Janeiro - UFRJ, 21941902, Rio de Janeiro, RJ, Brazil
| | - Renan Pioli
- Institute of Chemistry, Department of Organic Chemistry, University of São Paulo - USP, 05508-000, São Paulo, SP, Brazil
| | - Maysa Furlan
- Nuclei of Bioassays, Biosynthesis and Ecophysiology of Natural Products (NuBBE), Department of Organic Chemistry, Institute of Chemistry, Sao Paulo State University - UNESP, 14800-060, Araraquara, SP, Brazil
| | - Vanderlan da Silva Bolzani
- Nuclei of Bioassays, Biosynthesis and Ecophysiology of Natural Products (NuBBE), Department of Organic Chemistry, Institute of Chemistry, Sao Paulo State University - UNESP, 14800-060, Araraquara, SP, Brazil
| | - Chahrazade El Amri
- Sorbonne Université, UPMC Univ Paris 06-CNRS, IBPS, UMR 8256, Inserm ERL1164, B2A, 7 Quai Saint Bernard, F75005 Paris, France.
| | - Michèle Reboud-Ravaux
- Sorbonne Université, UPMC Univ Paris 06-CNRS, IBPS, UMR 8256, Inserm ERL1164, B2A, 7 Quai Saint Bernard, F75005 Paris, France.
| |
Collapse
|
12
|
Richy N, Sarraf D, Maréchal X, Janmamode N, Le Guével R, Genin E, Reboud-Ravaux M, Vidal J. Structure-based design of human immuno- and constitutive proteasomes inhibitors. Eur J Med Chem 2018; 145:570-587. [PMID: 29339252 DOI: 10.1016/j.ejmech.2018.01.013] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 01/04/2018] [Accepted: 01/04/2018] [Indexed: 12/20/2022]
Abstract
Starting from the X-ray structure of our previous tripeptidic linear mimics of TMC-95A in complex with yeast 20S proteasome, we introduced new structural features to induce a differential inhibition between human constitutive and immunoproteasome 20S particles. Libraries of 24 tripeptidic and 6 dipeptidic derivatives were synthesized. The optimized preparation of 3-hydroxyoxindolyl alanine residues from tryptophan and their incorporation in peptides were described. Several potent inhibitors of human constitutive proteasome and immunoproteasome acting at the nanomolar level (IC50 = 7.1 nM against the chymotrypsin-like activity for the best inhibitor) were obtained. A cytotoxic effect at the submicromolar level was observed against 6 human cancer cell lines.
Collapse
Affiliation(s)
- Nicolas Richy
- Université Rennes 1, Institut des Sciences Chimiques de Rennes, CNRS UMR 6226, Bâtiment 10A, Campus de Beaulieu, 35042 Rennes, Cedex, France
| | - Daad Sarraf
- Université Rennes 1, Institut des Sciences Chimiques de Rennes, CNRS UMR 6226, Bâtiment 10A, Campus de Beaulieu, 35042 Rennes, Cedex, France
| | - Xavier Maréchal
- Sorbonne Universités, UPMC Univ Paris 06-CNRS, IBPS, UMR 8256, Inserm ERL1164, B2A, 7 Quai Saint Bernard, F75005 Paris, France
| | - Naëla Janmamode
- Université Rennes 1, Institut des Sciences Chimiques de Rennes, CNRS UMR 6226, Bâtiment 10A, Campus de Beaulieu, 35042 Rennes, Cedex, France
| | - Rémy Le Guével
- Université Rennes 1, Technology Platform ImPACcell, SFR UMS CNRS 3480, INSERM 018, Bâtiment 8, Campus de Villejean, 35043 Rennes, Cedex, France
| | - Emilie Genin
- Université Rennes 1, Institut des Sciences Chimiques de Rennes, CNRS UMR 6226, Bâtiment 10A, Campus de Beaulieu, 35042 Rennes, Cedex, France
| | - Michèle Reboud-Ravaux
- Sorbonne Universités, UPMC Univ Paris 06-CNRS, IBPS, UMR 8256, Inserm ERL1164, B2A, 7 Quai Saint Bernard, F75005 Paris, France.
| | - Joëlle Vidal
- Université Rennes 1, Institut des Sciences Chimiques de Rennes, CNRS UMR 6226, Bâtiment 10A, Campus de Beaulieu, 35042 Rennes, Cedex, France.
| |
Collapse
|
13
|
Hovhannisyan AA, Pham TH, Bouvier D, Tan X, Touhar S, Mkryan GG, Dallakyan AM, El Amri C, Melikyan GS, Reboud-Ravaux M, Bouvier-Durand M. Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits. Bioorg Med Chem Lett 2017; 27:5172-5178. [PMID: 29113763 DOI: 10.1016/j.bmcl.2017.10.055] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Revised: 10/20/2017] [Accepted: 10/22/2017] [Indexed: 10/18/2022]
Abstract
New series of thiophene-containing phenoxypropanolamines were synthesized and evaluated for their potency to inhibit the three proteolytic activities of the mammalian 20S proteasome. Noticeable inhibition of both ChT-L and PA activities was obtained with three compounds: one with unsubstituted phenoxypropanolamine group (7) and the two others with a p-Cl-substituted group (4 and 9). For three other compounds (3, 8 and 10), ChT-L activity alone was significantly inhibited. In silico docking performed on the β5 and β1 subunits bearing the respective ChT-L and PA catalytic sites showed features common to poses associated with active compounds. These features may constitute a selectivity criterion for structure-guided inhibitor design.
Collapse
Affiliation(s)
- Anna A Hovhannisyan
- Department of Organic Chemistry, Yerevan State University, 1 Alex Manoogian Str., 0025 Yerevan, Armenia
| | - The Hien Pham
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, CNRS UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
| | - Dominique Bouvier
- Sorbonne Universités, UPMC Univ Paris 06, Atelier de BioInformatique, ISYEB, UMR 7205 CNRS MNHN UPMC EPHE, Museum national d'Histoire naturelle, CP 50, 45 rue Buffon, 75005 Paris Cedex 05, France
| | - Xiao Tan
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, CNRS UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
| | - SiAmmar Touhar
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, CNRS UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
| | - Gevorg G Mkryan
- The Scientific Technological Centre of Organic and Pharmaceutical Chemistry HAS A.L.Mnjoyan Institute of Fine Organic Chemistry, 26 Azatutyan Str., Yerevan 0014, Armenia
| | - Ashot M Dallakyan
- The Scientific Technological Centre of Organic and Pharmaceutical Chemistry HAS A.L.Mnjoyan Institute of Fine Organic Chemistry, 26 Azatutyan Str., Yerevan 0014, Armenia
| | - Chahrazade El Amri
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, CNRS UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
| | - Gagik S Melikyan
- Department of Organic Chemistry, Yerevan State University, 1 Alex Manoogian Str., 0025 Yerevan, Armenia
| | - Michèle Reboud-Ravaux
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, CNRS UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
| | - Michelle Bouvier-Durand
- Sorbonne Universités, UPMC Univ Paris 06, IBPS, CNRS UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France.
| |
Collapse
|
14
|
Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview. Molecules 2016; 21:molecules21070927. [PMID: 27438821 PMCID: PMC6274525 DOI: 10.3390/molecules21070927] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2016] [Revised: 07/11/2016] [Accepted: 07/12/2016] [Indexed: 01/10/2023] Open
Abstract
Proteasome emerged as an important target in recent pharmacological research due to its pivotal role in degrading proteins in the cytoplasm and nucleus of eukaryotic cells, regulating a wide variety of cellular pathways, including cell growth and proliferation, apoptosis, DNA repair, transcription, immune response, and signaling processes. The last two decades witnessed intensive efforts to discover 20S proteasome inhibitors with significant chemical diversity and efficacy. To date, the US FDA approved to market three proteasome inhibitors: bortezomib, carfilzomib, and ixazomib. However new, safer and more efficient drugs are still required. Computer-aided drug discovery has long being used in drug discovery campaigns targeting the human proteasome. The aim of this review is to illustrate selected in silico methods like homology modeling, molecular docking, pharmacophore modeling, virtual screening, and combined methods that have been used in proteasome inhibitors discovery. Applications of these methods to proteasome inhibitors discovery will also be presented and discussed to raise improvements in this particular field.
Collapse
|
15
|
Bisbenzimidazole derivatives as potent inhibitors of the trypsin-like sites of the immunoproteasome core particle. Biochimie 2015; 108:94-100. [DOI: 10.1016/j.biochi.2014.11.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2014] [Accepted: 11/05/2014] [Indexed: 02/05/2023]
|
16
|
Pace A, Buscemi S, Piccionello AP, Pibiri I. Recent Advances in the Chemistry of 1,2,4-OxadiazolesaaDedicated to Professor Nicolò Vivona on the occasion of his 75th birthday. ADVANCES IN HETEROCYCLIC CHEMISTRY 2015. [DOI: 10.1016/bs.aihch.2015.05.001] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
17
|
Desvergne A, Cheng Y, Grosay-Gaudrel S, Maréchal X, Reboud-Ravaux M, Genin E, Vidal J. Noncovalent Fluorescent Probes of Human Immuno- and Constitutive Proteasomes. J Med Chem 2014; 57:9211-7. [DOI: 10.1021/jm5011429] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Audrey Desvergne
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
- CNRS, UMR 8256, Biological Adaptation and Ageing (B2A), 75005 Paris, France
| | - Yan Cheng
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
- CNRS, UMR 8256, Biological Adaptation and Ageing (B2A), 75005 Paris, France
| | - Sophie Grosay-Gaudrel
- Université de Rennes 1, CPM, Bâtiment 10A, Campus de Beaulieu, 35042 Rennes Cedex, France
- CNRS, UMR 6510, Chimie et Photonique Moléculaires, 35042 Rennes, France
| | - Xavier Maréchal
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
- CNRS, UMR 8256, Biological Adaptation and Ageing (B2A), 75005 Paris, France
| | - Michèle Reboud-Ravaux
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, Biological Adaptation and Ageing (B2A), Integrated Cellular Ageing and Inflammation, 7 Quai St Bernard, 75005 Paris, France
- CNRS, UMR 8256, Biological Adaptation and Ageing (B2A), 75005 Paris, France
| | - Emilie Genin
- Université de Rennes 1, CPM, Bâtiment 10A, Campus de Beaulieu, 35042 Rennes Cedex, France
- CNRS, UMR 6510, Chimie et Photonique Moléculaires, 35042 Rennes, France
| | - Joëlle Vidal
- Université de Rennes 1, CPM, Bâtiment 10A, Campus de Beaulieu, 35042 Rennes Cedex, France
- CNRS, UMR 6510, Chimie et Photonique Moléculaires, 35042 Rennes, France
| |
Collapse
|
18
|
Villoutreix BO, Kuenemann MA, Poyet JL, Bruzzoni-Giovanelli H, Labbé C, Lagorce D, Sperandio O, Miteva MA. Drug-Like Protein-Protein Interaction Modulators: Challenges and Opportunities for Drug Discovery and Chemical Biology. Mol Inform 2014; 33:414-437. [PMID: 25254076 PMCID: PMC4160817 DOI: 10.1002/minf.201400040] [Citation(s) in RCA: 84] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2014] [Accepted: 04/21/2014] [Indexed: 12/13/2022]
Abstract
[Formula: see text] Fundamental processes in living cells are largely controlled by macromolecular interactions and among them, protein-protein interactions (PPIs) have a critical role while their dysregulations can contribute to the pathogenesis of numerous diseases. Although PPIs were considered as attractive pharmaceutical targets already some years ago, they have been thus far largely unexploited for therapeutic interventions with low molecular weight compounds. Several limiting factors, from technological hurdles to conceptual barriers, are known, which, taken together, explain why research in this area has been relatively slow. However, this last decade, the scientific community has challenged the dogma and became more enthusiastic about the modulation of PPIs with small drug-like molecules. In fact, several success stories were reported both, at the preclinical and clinical stages. In this review article, written for the 2014 International Summer School in Chemoinformatics (Strasbourg, France), we discuss in silico tools (essentially post 2012) and databases that can assist the design of low molecular weight PPI modulators (these tools can be found at www.vls3d.com). We first introduce the field of protein-protein interaction research, discuss key challenges and comment recently reported in silico packages, protocols and databases dedicated to PPIs. Then, we illustrate how in silico methods can be used and combined with experimental work to identify PPI modulators.
Collapse
Affiliation(s)
- Bruno O Villoutreix
- Université Paris Diderot, Sorbonne Paris Cité, UMRS 973 InsermParis 75013, France
- Inserm, U973Paris 75013, France
- CDithem, Faculté de Pharmacie, 1 rue du Prof Laguesse59000 Lille, France
| | - Melaine A Kuenemann
- Université Paris Diderot, Sorbonne Paris Cité, UMRS 973 InsermParis 75013, France
- Inserm, U973Paris 75013, France
| | - Jean-Luc Poyet
- Université Paris Diderot, Sorbonne Paris Cité, UMRS 973 InsermParis 75013, France
- Inserm, U973Paris 75013, France
- IUH, Hôpital Saint-LouisParis, France
- CDithem, Faculté de Pharmacie, 1 rue du Prof Laguesse59000 Lille, France
| | - Heriberto Bruzzoni-Giovanelli
- Université Paris Diderot, Sorbonne Paris Cité, UMRS 973 InsermParis 75013, France
- Inserm, U973Paris 75013, France
- CIC, Clinical investigation center, Hôpital Saint-LouisParis, France
| | - Céline Labbé
- Université Paris Diderot, Sorbonne Paris Cité, UMRS 973 InsermParis 75013, France
- Inserm, U973Paris 75013, France
| | - David Lagorce
- Université Paris Diderot, Sorbonne Paris Cité, UMRS 973 InsermParis 75013, France
- Inserm, U973Paris 75013, France
| | - Olivier Sperandio
- Université Paris Diderot, Sorbonne Paris Cité, UMRS 973 InsermParis 75013, France
- Inserm, U973Paris 75013, France
- CDithem, Faculté de Pharmacie, 1 rue du Prof Laguesse59000 Lille, France
| | - Maria A Miteva
- Université Paris Diderot, Sorbonne Paris Cité, UMRS 973 InsermParis 75013, France
- Inserm, U973Paris 75013, France
| |
Collapse
|
19
|
Pautasso C, Troia R, Genuardi M, Palumbo A. Pharmacophore modeling technique applied for the discovery of proteasome inhibitors. Expert Opin Drug Discov 2014; 9:931-43. [PMID: 24877566 DOI: 10.1517/17460441.2014.923838] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
INTRODUCTION The 26S proteasome has many important roles in the biological functions of the cells, and proteasome inhibitors have multiple and complex activities on cells. These compounds can be natural or synthesized. Most synthetic derivatives have been rationally designed, synthesized and optimized to obtain the best selectivity and increase the activity. The design of chemical entities with desired molecular identification, which plays an important role in biological systems, is provided by pharmacophore modeling. Indeed, pharmacophore models can be established either in a ligand-based manner or in a receptor-based manner. AREAS COVERED The authors discuss the application of pharmacophore modeling techniques to proteasome inhibitors development. Furthermore, the article reviews the classification of the currently discovered proteasome inhibitors where the principal mechanism of action and clinical application are represented. EXPERT OPINION In the era of new drug development, database of compounds should be thoroughly evaluated with a combination of methods that consider both pharmacophore- and ligand-based virtual screening. The concept of pharmacophore helps to discover new active compounds and to evaluate their activity. The nature of proteasome inhibitor pharmacophore affects the secondary active-site specificity; indeed, increasing specificity decreases the cytotoxicity of the proteasome inhibitors. It is hypothesized that the balanced simultaneous modulation of a few druggable targets may have superior efficacy and fewer side effects than single-target or combination therapies for the treatment of human cancers. The discovery of new compounds should aim to find more active compounds that improve the compliance of patients.
Collapse
Affiliation(s)
- Chiara Pautasso
- University of Torino, Myeloma Unit, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Division of Hematology , Torino , Italy ;
| | | | | | | |
Collapse
|
20
|
Micale N, Scarbaci K, Troiano V, Ettari R, Grasso S, Zappalà M. Peptide-Based Proteasome Inhibitors in Anticancer Drug Design. Med Res Rev 2014; 34:1001-69. [DOI: 10.1002/med.21312] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Nicola Micale
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| | - Kety Scarbaci
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| | - Valeria Troiano
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| | - Roberta Ettari
- Dipartimento di Scienze Farmaceutiche; Università degli Studi di Milano; Via Mangiagalli 25 20133 Milano Italy
| | - Silvana Grasso
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| | - Maria Zappalà
- Dipartimento di Scienze del Farmaco e dei Prodotti per la Salute; Università degli Studi di Messina; Viale Annunziata 98168 Messina Italy
| |
Collapse
|
21
|
Hovhannisyan A, Pham TH, Bouvier D, Piroyan A, Dufau L, Qin L, Cheng Y, Melikyan G, Reboud-Ravaux M, Bouvier-Durand M. New C(4)- and C(1)-derivatives of furo[3,4-c]pyridine-3-ones and related compounds: evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform. Bioorg Med Chem Lett 2014; 24:1571-80. [PMID: 24534487 DOI: 10.1016/j.bmcl.2014.01.072] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2013] [Revised: 01/22/2014] [Accepted: 01/23/2014] [Indexed: 01/24/2023]
Abstract
A set of 18 new C(4) and C(1) derivatives of nor-cerpegin (1,1-dimethyl furo[3,4-c]pyridine-3-one), 6 model compounds (γ- and δ-lactones) and 20 furo- or thieno[2,3-d]-pyrimidine-4-one related compounds were designed and synthesized. Each compound was assayed for inhibition of CT-L, T-L and PA proteolytic activities of 20S constitutive proteasome (c20S). Most performant compounds were also assayed on 20S immunoproteasome (i20S). Compound 10 with a benzylamino group at C(4) and dimethylated at C(1) of the furopyridine ring was the most efficient PA site-specific inhibitor of the c20S (IC50(cPA) of 600nM) without noticeable inhibition of the i20S PA site (iPA). In silico docking assays for 10 at the iPA catalytic site revealed the absence of poses normally observed for this compound and related ones at the constitutive PA site (cPA). The thieno[2,3-d]pyrimidine-4-one 40 was T-L site-specific with a mild inhibition of both c20S and i20S in vitro (IC50(cT-L) of 9.9μM and IC50(iT-L) of 6.7μM). In silico docking assays of 40 at T-L sites of c20S and i20S revealed almost identical first rank poses in the two types of sites with no possibility left for nucleophilic attack by Thr1 as observed for the fused furopyridine-3-one 10.
Collapse
Affiliation(s)
- Anna Hovhannisyan
- Department of Organic Chemistry, Yerevan State University, A. Manoogian Str. 1, 0025 Yerevan, Armenia.
| | - The Hien Pham
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, ERL U1164, B2A, Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology, Case 256, 7 Quai St Bernard, F-75005 Paris, France; CNRS, UMR 8256, B2A, Biological Adaptation and Ageing, F-75005 Paris, France.
| | - Dominique Bouvier
- Sorbonne Universités, UPMC Univ Paris 06, Atelier de Bioinformatique, Case courrier 1202, 4 Place Jussieu, F 75252 Paris Cedex 05, France.
| | - Alexander Piroyan
- Department of Organic Chemistry, Yerevan State University, A. Manoogian Str. 1, 0025 Yerevan, Armenia.
| | - Laure Dufau
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, ERL U1164, B2A, Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology, Case 256, 7 Quai St Bernard, F-75005 Paris, France; CNRS, UMR 8256, B2A, Biological Adaptation and Ageing, F-75005 Paris, France.
| | - Lixian Qin
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, ERL U1164, B2A, Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology, Case 256, 7 Quai St Bernard, F-75005 Paris, France; CNRS, UMR 8256, B2A, Biological Adaptation and Ageing, F-75005 Paris, France.
| | - Yan Cheng
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, ERL U1164, B2A, Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology, Case 256, 7 Quai St Bernard, F-75005 Paris, France; CNRS, UMR 8256, B2A, Biological Adaptation and Ageing, F-75005 Paris, France.
| | - Gagik Melikyan
- Department of Organic Chemistry, Yerevan State University, A. Manoogian Str. 1, 0025 Yerevan, Armenia.
| | - Michèle Reboud-Ravaux
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, ERL U1164, B2A, Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology, Case 256, 7 Quai St Bernard, F-75005 Paris, France; CNRS, UMR 8256, B2A, Biological Adaptation and Ageing, F-75005 Paris, France.
| | - Michelle Bouvier-Durand
- Sorbonne Universités, UPMC Univ Paris 06, UMR 8256, ERL U1164, B2A, Biological Adaptation and Ageing, Integrated Cellular Ageing and Inflammation, Molecular & Functional Enzymology, Case 256, 7 Quai St Bernard, F-75005 Paris, France; CNRS, UMR 8256, B2A, Biological Adaptation and Ageing, F-75005 Paris, France.
| |
Collapse
|
22
|
Bordessa A, Keita M, Maréchal X, Formicola L, Lagarde N, Rodrigo J, Bernadat G, Bauvais C, Soulier JL, Dufau L, Milcent T, Crousse B, Reboud-Ravaux M, Ongeri S. α- and β-hydrazino acid-based pseudopeptides inhibit the chymotrypsin-like activity of the eukaryotic 20S proteasome. Eur J Med Chem 2013; 70:505-24. [DOI: 10.1016/j.ejmech.2013.09.059] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2013] [Revised: 09/23/2013] [Accepted: 09/24/2013] [Indexed: 10/26/2022]
|
23
|
Villoutreix BO, Lagorce D, Labbé CM, Sperandio O, Miteva MA. One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade. Drug Discov Today 2013; 18:1081-9. [PMID: 23831439 DOI: 10.1016/j.drudis.2013.06.013] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2013] [Revised: 06/18/2013] [Accepted: 06/26/2013] [Indexed: 12/17/2022]
Abstract
Online resources enabling and supporting drug discovery have blossomed during the past ten years. However, drug hunters commonly find themselves overwhelmed by the proliferation of these computer-based resources. Ten years ago, we, the authors of this review, felt that a comprehensive list of in silico resources relating to drug discovery was needed. Especially because the internet provides a wealth of inspiring tools that, if fully exploited, could greatly assist the process. We present here a compilation of online tools and databases collected over the past decade. The tools were essentially found through literature and internet searches and, currently, our list contains over 1500 URLs. We also briefly highlight some recently reported services and comment about ongoing and future efforts in the field.
Collapse
Affiliation(s)
- Bruno O Villoutreix
- Université Paris Diderot, Sorbonne Paris Cité, Inserm UMR-S 973, Molécules Thérapeutiques In Silico, 39 rue Helene Brion, 75013 Paris, France.
| | | | | | | | | |
Collapse
|